TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00478322

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of 100 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 100 mg BID
Study: NCT00093132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin
Description: Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
Study: NCT01250847

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Quetiapine(Seroquel-XR) 50~800mg a day
Description: The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine(Seroquel-XR) 50~800mg a day
Description: The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine(Seroquel-XR) 50~800mg a day
Description: The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.
Study: NCT03911908

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral oximetry (near infrared) based CPR-Algorithm
Description: If NIRS values do not increase over time until ROSC (target: \>40 % after 10 min), interventions are suggested in a modified CPR/NIRS algorithm.
Study: NCT02181998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full dose tenecteplase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full dose tenecteplase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractioned heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study: NCT01093170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNA-144101
Description: Intravitreous administration of RNA-144101
Study: NCT00696228

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MUFA
Description: MUFA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA
Description: PUFA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SFA
Description: SFA
Study: NCT02223364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve blocks with Bupivacaine
Description: Subjects received Bupivacaine 0.5% preoperatively, then Bupivacaine 0.2% upon post anesthesia care unit (PACU) arrival via femoral nerve block, then Bupivacaine 0.25% via single-injection sciatic nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra articular injection with Ropivacaine
Description: Subjects received an intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Ropivacaine dose depended upon body weight: 50-74.9 kg: 200 mg, 75-99.9 kg: 300 mg, 100-125 kg: 400 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra articular injection with liposomal bupivacaine
Description: Subjects received an intra articular injection with liposomal bupivacaine, a total volume of 120 mL injected in the periarticular structures by the surgeon. Patients weighing 50-125 kg received 266mg of Liposomal Bupivacaine.
Study: NCT04092088

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS-r
Description: The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS-r
Description: The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS-r
Description: Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS-r
Description: Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS-s
Description: The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS-s
Description: The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS-s
Description: Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS-s
Description: Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).
Study: NCT02683148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-67 validated survey
Description: * Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~* 7 questions with answers ranging from 0=Not At All to 4 = Very Much.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-67 validated survey
Description: * Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~* 7 questions with answers ranging from 0=Not At All to 4 = Very Much.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-67 validated survey
Description: * Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~* 7 questions with answers ranging from 0=Not At All to 4 = Very Much.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-67 validated survey
Description: * Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~* 7 questions with answers ranging from 0=Not At All to 4 = Very Much.
Study: NCT01473394

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose-matched placebo
Description: Dose-matched placebo was supplied as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone was supplied as tablets.
Study: NCT00803309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha-2b
Description: 1.5 µg/kg once weekly, syringe, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800-1400 mg per os, daily, tablets, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated Interferon alpha-2b
Description: 1.5 µg/kg once weekly, syringe, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800-1400 mg per os, daily, tablets, 12 weeks
Study: NCT02398370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)
Study: NCT01522235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double blinded IVIg
Description: Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.

Intervention type: OTHER
Group type: OTHER
Intervention: Double blinded Placebo
Description: Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Blinded IVIg
Description: This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.

Intervention type: OTHER
Group type: OTHER
Intervention: Single Blinded IVIg
Description: This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
Study: NCT02342977

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will randomly receive placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Patients will randomly receive lacosamide
Study: NCT04038554

Intervention type: DIAGNOSTIC_TEST
Intervention: Feces and saliva analysis
Description: Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Feces and saliva analysis
Description: Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
Study: NCT03742817

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: e-Cigarette
Description: Participants will self-administer an experimenter-provided e-cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Cigarette
Description: Participants will self-administer an experimenter-provided e-cigarette.
Study: NCT03853902

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Program
Description: Mindfulness Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Program
Description: Mindfulness Program
Study: NCT02498509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-342
Description: treatment for 4 weeks after randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Description: treatment for 4 weeks after randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocabastine HCL
Description: treatment for 4 weeks after randomization
Study: NCT02673242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold IMT Philips Respironics
Description: Inspiratory muscle training
Study: NCT01451164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: orally administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: orally administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: orally administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally administered once daily
Study: NCT03402347

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-ionising radiation
Description: Laser regimes will be applied to ex vivo skin samples.
Study: NCT03409939

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aromatic Amino Acid Intake
Description: Intakes will be randomly chosen from a list of 8 doses of aromatic amino acids. Each intake will will be repeated approximately 4 times.
Study: NCT01985958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT03313011

Intervention type: DIAGNOSTIC_TEST
Intervention: Testing protocol for the study
Description: All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
Study: NCT04413383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Curved Iris Scissors
Description: Aesculap Curved Iris Scissors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wuennenberg Modified Curved Iris Scissors
Description: Modified Silent Curved Iris Scissors

Intervention type: OTHER
Group type: OTHER
Intervention: Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors
Description: Patients experience both types of scissors
Study: NCT01821950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga during physical education
Description: 12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
Study: NCT03955965

Intervention type: OTHER
Intervention: Medication reconciliation
Description: No intervention was performed other than collecting data on patients' medical files
Study: NCT03098017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short pasta (dry)
Description: 50g available carbohydrate portion of penne (\~71g uncooked) will be cooked according to package instructions and served with 500mL water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long pasta (dry)
Description: 50g available carbohydrate portion of spaghetti (\~71g uncooked) will be cooked according to package instructions and served with 500mL water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Couscous
Description: 50g available carbohydrate portion of couscous (\~70g uncooked) will be cooked according to package instructions and served with 500mL water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 50g available carbohydrate portion of glucose monohydrate (\~55g) will be dissolved in 500mL water
Study: NCT04412642

Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyflurane, MEOF
Description: As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
Study: NCT00722163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: befriending
Study: NCT03376373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neurofeedback
Description: real-time feedback on accuracy of emotion recognition
Study: NCT02397291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannose
Description: A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myoinositol
Description: A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04312841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Given PO
Study: NCT00998348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Program
Description: The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
Study: NCT03742817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Cigarette
Description: Participants will self-administer an experimenter-provided e-cigarette.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-Cigarette
Description: Participants will self-administer an experimenter-provided e-cigarette.
Study: NCT01269255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 with Cisplatin
Description: SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)~* Step 1: Chemotherapy; TS-1/CDDP #2 cycles~* Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP~* Step 3: Surgery therapy
Study: NCT04191122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPESS
Description: The intervention includes brief psychotherapy to be delivered within primary care settings
Study: NCT00717275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
Study: NCT04240275

Intervention type: DEVICE
Intervention: Reliability of the G-Walk device in children with Cerebral Palsy
Description: The purpose of this study was to confirm the test-retest reliability of a commercially available body-worn sensor-G-Walk® sensor system-for spatiotemporal gait parameters in children with CP.~The children will be assessed with the G-Walk on two separate occasions.For the reliability analysis, the second measurement tests will be repeated 3 days after the first assessment.~The device is placed on an elastic belt and worn on the waist of the person being evaluated, with the center of the device at the fifth lumbar vertebrae. To ensure correct placement of the device, the L4-L5 intervertebral space will be palpated via the posterior superior iliac spines (SIPS).~After the accelerometer is placed, the children are asked to walk calmly at normal speed, on a 10 m track, whose boundaries will be determined with colored lines and to return to the starting position.
Study: NCT01649310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
Study: NCT02947906

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00782691

Intervention type: OTHER
Intervention: CT-FDG/PET scan of the head-and-neck region
Description: CT-FDG/PET scan of the head-and-neck region
Study: NCT03652584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Study: NCT00176475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
Study: NCT00337285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse (lisdexamfetamine dimesylate), NRP104
Description: NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
Study: NCT03023202

Intervention type: OTHER
Intervention: PMMTB (Precision Medicine Molecular Tumor Board)
Description: PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.